SEC Tracker
Get the app
CRON · XBRL financial data

Cronos Group financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CRON's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers2524*25283430*32333645*4553
Gross profit4—464—141518—1928
Research and development11*1111*1111*11
General and administrative1410*9131312*911913*1211
Total operating expenses2624*20223722*18201924*2121
Operating income (loss)(22)(22)*(16)(16)(34)(11)*(4)(5)(1)(7)*(2)7
Other income (expense)10*(1)0(0)0*0(0)(0)0*0(0)
Income tax expense (benefit)(1)(0)*(1)(2)(3)2*(0)(1)(1)(12)*20
Net income (loss)(2)(45)*(2)(9)844*6(40)26(2)*1432
Earnings per share, basic USD per share0.00(0.12)*(0.01)(0.02)0.020.11*0.02(0.10)0.070.00*0.040.09
Earnings per share, diluted USD per share0.00(0.12)*(0.01)(0.02)0.020.11*0.02(0.10)0.070.00*0.040.09
Weighted average shares, basic millions of shares381381*381382382382*383385383383*379374
Weighted average shares, diluted millions of shares381381*381382386393*387385385377*382375

Balance sheet

CSV

Fiscal quarters (CRON's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents572669855848862859798794784792822467
Short-term investments2681920000404040400330
Accounts receivable161415162015192727343337
Inventory363031294733354248474953
Prepaid and other current assets656576659855
Total current assets918933942935959936919927922944928912
Property and equipment, net56593737163133139150146146142142
Right-of-use asset111111122111
Goodwill11113863636765666564
Total assets1,1501,1401,1091,0911,1841,1661,1541,1751,1781,1971,1721,180
Accounts payable5129871791211121017
Accrued liabilities242823243232232530363135
Total current liabilities314133334050333841484256
Lease liability, non-current221111111111
Total liabilities334436355355394546544862
Retained earnings462417414406414458464424450448461492
Total stockholders' equity1,1201,1001,0761,0591,0821,0641,0661,0821,0831,0941,0741,069
Total liabilities and equity1,1501,1401,1091,0911,1841,1661,1541,1751,1781,1971,1721,180
Common shares outstanding (cover page) millions of shares381381382382382383385383383379374368

Cash flows

CSV

Fiscal quarters (CRON's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(2)(45)*(2)(9)844*6(40)26(2)*1432
Stock-based compensation2*2*22*2*2*21*2*1*12*
Depreciation and amortization2*1*22*4*3*34*4*4*43*
Net cash from operating activities(0)*17*(2)2*12*8*(2)3*13*12*1124*
Purchases of property and equipment(0)*1*21*6*4*154*4*2*22*
Net cash from investing activities158*82*190(9)*(1)*(5)*(55)(1)*(23)*3*38(358)*
Share repurchases—year only——0*0*04*2*4*1716*
Net cash from financing activities(0)*(0)*(1)(0)*(0)*(0)*(3)(8)*(2)*(7)*(18)(21)*
Net change in cash162*98*186(7)*14*(3)*(61)(3)*(10)*8*30(355)*

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Cronos Group4675324*368.4M— 10-QJun 30, 2026
REGENXBIO36108(62)*66.0M1.7 quarters 10-QJun 30, 2026
CytomX Therapeutics171.4(18)*217.9M18.3 quarters 10-QJun 30, 2026
Oruka Therapeutics268not reported(33)*66.2M26.4 quarters 10-QJun 30, 2026
Capricor Therapeutics21not reported(31)*58.1M7.6 quarters 10-QJun 30, 2026
Cryoport269491.1*50.6M— 10-QJun 30, 2026
CytoDyn16not reported(7.7)1.5B2.1 quarters 10-QAug 31, 2026
Emergent BioSolutions176110100*51.4M— 10-QSep 30, 2026
Northwest Biotherapeutics0.60.8(7.2)*1.7B0.1 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.